Clinical trials: Stereotactic Body Radiotherapy
Pancreatic Cancer
Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer
This prospective, multicenter clinical study evaluates the efficacy and safety of NALIRIFOX in combination with Stereotactic Body Radiation Therapy (SBRT) for patients with locally advanced unresectable pancreatic cancer.
- Trial name
- RAD-NALIRIFOX (NCT07173387)
- Testing
- NALIRIFOX (liposomal irinotecan-based chemotherapy)., Stereotactic Body Radiation Therapy (SBRT).
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatocellular Carcinoma
Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality and the sixth most prevalent cancer in the world.
- Trial name
- NCT05433701
- Testing
- Stereotactic Body Radiotherapy, Radiofrequency Ablation
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Jonggi Choi
Thoracic Cancer, Abdominal Cancer
VisionRT-based Deep Inspiration Breath-hold (DIBH) Respiratory Motion Management Strategy, A Pilot Study for Thoracic and Abdominal Tumors
A more recent competing technology for implementing the DIBH technique is real-time surface photogrammetry using the AlignRT system (Vision RT Ltd., London, UK).
- Trial name
- NCT04686500
- Testing
- Tidal volume measured by spirometer and DIBH surface from CT image
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Texas Southwestern Medical Center
Carcinoma, Non-Small-Cell Lung
A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is safe, effective in the treatment of stage IV…
- Trial name
- NCT02623595
- Testing
- Stereotactic body radiotherapy, rhGM-CSF
- Where
- China
- Sponsor
- Wuhan University
Lung Carcinoma, Malignant Respiratory Tract Neoplasm
Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer
This pilot phase I/II trial studies how well a continuous positive airway pressure device or deep inspiration breath hold works in reducing tumor movement in patients undergoing stereotactic body radiation therapy (SBRT) for lung…
- Conditions
- Lung Carcinoma, Malignant Respiratory Tract Neoplasm, Metastatic Malignant Neoplasm in the Lung
- Trial name
- NCT03422302
- Testing
- Biphasic Positive Airway Pressure, Computed Tomography, Continuous Positive Airway Pressure
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Stereotactic Body Radiation Therapy (SBRT), Spinal Metastases
Efficacy and Safety of Stereotactic Body Radiation Therapy for Spinal Metastases With Bilsky Grade 1c-3
This prospective, multicenter, single-arm phase II clinical trial is designed to enroll patients with spinal metastases classified as Bilsky grade 1c-3 who will receive stereotactic body radiation therapy (SBRT).
- Trial name
- NCT07809672
- Testing
- SBRT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Bone Cancer
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
This research study is studying a form of radiation therapy called stereotactic body radiation therapy or SBRT as a possible treatment for Cancer that has spread to the spine or other bone
- Trial name
- NCT02880319
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Stereotactic Linear Accelerator
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dana-Farber Cancer Institute
Hepatocellular Carcinoma
A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma
Notable-HCC is a phase Ib study of neoadjuvant stereotactic body radiotherapy (SBRT) plus Programmed cell death-1 (PD-1, Tislelizumab, BeiGene) prior to hepatic resection in patients with resectable HCC.
- Trial name
- Notable-HCC (NCT05185531)
- Testing
- PD-1 plus stereotactic body radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong Cancer Hospital and Institute
Prostate Cancer (Adenocarcinoma)
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.
- Trial name
- DE-CART (NCT07219303)
- Testing
- adaptive stereotactic body radiation therapy (SBRT) with a SIB
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Fox Chase Cancer Center
Stereotactic Body Radiotherapy, PD-1 Inhibitors
Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer
The goal of this observational study is to investigate the efficacy and safety of stereotactic body radiotherapy combined with PD-1 blockers for LAPC and LRPC.
- Conditions
- Stereotactic Body Radiotherapy, PD-1 Inhibitors, Pancreatic Cancer
- Trial name
- NCT06195254
- Testing
- Stereotactic body radiotherapy (SBRT), PD-1 blocking antibody
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Peking University Third Hospital
Prostate Adenocarcinoma
Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer
The LDR BURST trial will compare the side effects of two radiotherapy treatments for men with localised prostate cancer. The first treatment is 4D low dose rate brachytherapy where small radioactive seeds are inserted into the…
- Trial name
- LDR BURST (NCT07210502)
- Testing
- 4D Low Dose Rate Prostate Brachytherapy, Ultra-hypofractionated Radiotherapy
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Pancreatic Cancer
SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients
When gemcitabine based chemo and fluorouracil based chemo regimes are failed in late-stage or recurrent pancreatic cancer patients, there is no alternative options. Anti-PD-1 antibody has became a promising anti-cancer drug.
- Trial name
- CISPD-2 (NCT03716596)
- Testing
- SBRT, anti-PD-1 antibody
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Carcinoma, Non-Small-Cell Lung
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II…
- Trial name
- PACIFIC-4 (NCT03833154)
- Testing
- Durvalumab, (Osimertinib cohort, single-arm, open-label separate cohort)
- Where
- 209 sites in United States, Australia and 18 more
- Volunteers
- 724 people
- Sponsor
- AstraZeneca
Pancreatic Neoplasms
Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region
This is a single center, single arm unblinded prospective study of the safety of pancreatic stereotactic body radiation therapy (SBRT) in patients with unresectable, borderline resectable, or recurrent pancreatic/periampullary…
- Trial name
- NCT02780648
- Testing
- Stereotactic Body Radiation
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Indiana University